Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 169,352 shares, a decrease of 15.8% from the January 29th total of 201,250 shares. Based on an average daily volume of 1,241,703 shares, the short-interest ratio is presently 0.1 days. Currently, 4.8% of the company’s stock are sold short. Currently, 4.8% of the company’s stock are sold short. Based on an average daily volume of 1,241,703 shares, the short-interest ratio is presently 0.1 days.

Ensysce Biosciences Stock Performance

NASDAQ ENSC traded down $0.01 during trading hours on Wednesday, hitting $0.50. The company had a trading volume of 855,463 shares, compared to its average volume of 8,293,433. The firm has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $1.55. Ensysce Biosciences has a 52 week low of $0.31 and a 52 week high of $5.29. The firm has a market capitalization of $1.83 million, a price-to-earnings ratio of -0.08 and a beta of 1.14.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Ensysce Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in ENSC. TRU Independence Asset Management 2 LLC purchased a new position in Ensysce Biosciences during the third quarter worth about $25,000. Citadel Advisors LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $34,000. Virtu Financial LLC purchased a new position in shares of Ensysce Biosciences during the third quarter worth about $34,000. DRW Securities LLC raised its stake in Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.